Legend Biotech CFO Lori Macomber to Resign, Jessie Yeung Named Interim CFO

Published on 24/12/2024 at 16:36 - Modified on 24/12/2024 at 16:37

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Legend Biotech Corporation

US lawmakers renew concerns about GenScript's ties to China	07-09	RE
RBC Lowers Price Target on Legend Biotech to $75 From $78, Keeps Outperform Rating	07-07	MT
UBS Lowers Price Target on Legend Biotech to $54 From $60, Maintains Buy Rating	07-03	MT
Legend Biotech Provides Update on REMS for Currently Approves BCMA- and CD19-Directed Autologous Chimeric Antigen Receptor T Cell Immunotherapies	06-30	CI
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)	06-30	RE
Legend Biotech Valuation Presents 'Buying Opportunity,' RBC Analysts Say	06-26	MT
SPIC Yuanda Environmental Protection Names Chief Accountant	06-16	MT
Legend Biotech Corporation Appoints Peter Salovey as Lead Independent Director, Effective June 5, 2025	06-05	CI
Genscript Biotech's Myeloma Drug Shows Progression-Free Survival in One-Third of Patients During Study	06-04	MT
Legend Biotech Reports 5-Year Survival Data for Carvykti in Multiple Myeloma	06-03	MT
Legend Biotech Corporation Unveils 5-Year Survival Data for Carvykti®? in Multiple Myeloma At 2025 Asco Annual Meeting	06-03	CI
Legend Biotech Corporation to Present New Data on Carvykti for Patients with Multiple Myeloma At 2025 Asco and Eha Annual Meeting	05-23	CI
Legend Biotech Corporation Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT	05-22	CI
Legend Biotech Corporation, Q1 2025 Earnings Call, May 13, 2025	05-21
Legend Biotech Shares Have 'Meaningful Upside' With Continued Execution, RBC Says	05-16	MT
Legend Biotech Corporation Intends to Use Premises as Its New Global Corporate Headquarters	05-14	CI
Truist Securities Adjusts Legend Biotech Price Target to $71 From $88, Maintains Buy Rating	05-14	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	05-13	MT
Legend Biotech Corporation Q1 Net Income USD -100.916 Million	05-13	RE
Legend Biotech Q1 Loss Narrows, Revenue Rises	05-13	MT
Earnings Flash (LEGN) Legend Biotech Posts Q1 Adjusted Net Loss $0.07 a Share, vs. FactSet Est of $0.21 Loss	05-13	MT
Earnings Flash (LEGN) Legend Biotech Reports Q1 Revenue $195.1M, vs. FactSet Est of $193.6M	05-13	MT
Legend Biotech Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	05-13	CI
Genscript Biotech Associate Logs $369 Million in Q1 Sales of CARVYKTI	04-16	MT
Legend Biotech Says Carvykti Sales Reach $369 Million	04-15	MT